Navigation Links
Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
Date:12/21/2009

change rates. For additional information about the factors that affect the company's business, please see the company's latest Form 10-K, filed February 2009, and Form 10-Q filed October 2009. The company undertakes no duty to update forward-looking statements.

Incyte Safe Harbor Statement

Except for the historical information contained herein, the matters set forth in this press release, including statements with respect to with respect to the potential for Incyte to receive up to $665 million in additional potential milestones, Incyte's expectation for the earliest time for it to consider exercising a co-development option, Incyte's confidence that the full therapeutic and commercial potential of INCB28050 in RA as well as other inflammatory conditions can be rapidly and effectively achieved through the collaboration agreement, and the potential for JAK inhibitors to be useful for the treatment of a broad range of inflammatory conditions, are all forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause the parties not to achieve some or all of the commercial and developmental milestones set forth in the collaboration agreement and that may otherwise cause Incyte's actual results and timing to differ materially, including the high degree of risk and uncertainty associated with drug development and clinical trials, the uncertainty associated with the regulatory approval processes, risks related to the timing of and patient enrollment in clinical trials, risks related to the potential failure of INCB28050 to demonstrate safety and efficacy in clinical testing, risks and uncertainty associated with the therapeutic and commercial value of INCB28050, risks relating to Lilly's and Incyte's abilities to successfully develop and commercialize drug candidates, risks relating to market compe
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
(Date:8/29/2014)... Aug. 29, 2014   Vittamed Corporation , a neurodiagnostics ... announced today that T. (Teo) Forcht Dagi , MD, ... Board of Directors. " Teo Forcht Dagi ... neurosurgery, medical innovation and venture capital," said Remis Bistras ... to add his clinical, strategic, and entrepreneurial expertise to our ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct ... and other chronic wounds by the Saudi Food and Drug ... a living cell based product used by physicians to heal ... world. "With diabetes being a widespread and growing ...
... 28 Boston Scientific Corporation (NYSE: BSX ... long-term data from the MADIT II clinical trial in ... demonstrates that the life-saving benefits of implantable cardioverter defibrillator ... the first time that long-term data regarding the benefits ...
Cached Medicine Technology:Apligraf® Approved by Saudi Food and Drug Authority for Treatment of Chronic Wounds 2Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 2Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 3
(Date:8/29/2014)... As reported by the Frederick News Post in the ... (8/17), a graduate of the Frederick County Drug Treatment Court has ... with the program. The graduate, Korey Shorb, put together a race ... walk. He plans to donate the proceeds of the event to ... helped him. Shorb, who graduated in 2008, admitted that he would ...
(Date:8/29/2014)... 30, 2014 Market Research Report ... is a professional and in-depth market survey on ... firstly reviews the basic information of Glass microfiber ... report then explores global and China’s top manufacturers ... Production value, and market share etc. , The ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... G. Rodas. Dr. Rodas will be practicing out of ... As a member of Healthpointe’s orthopedic team, ... internal medicine, and board-certified in occupational medicine. , ... title as Medical Director of Raytheon, the world-class defense ...
(Date:8/29/2014)... 2014 Dr. Parsa Mohebi M.D. has developed ... loss achieve great results in hair transplantation. One of ... , an FUE method that harvests facial hair for transplanting ... lets patients whose hair loss classification is 5 and above ... a great alternative for those advanced hair loss patients who ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe ... Chapman University Physical Therapy students via Clinical Rotations. ... University will be shadowing Healthpointe providers and specialists ... them to develop clinical experience and learn professional ... students will gain insight into several patient care ...
Breaking Medicine News(10 mins):Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2
... A large, national multi-center study of thousands of children ... has found that most of those with normal computed ... observation. Of the more than 13,500 children included ... abnormal CT scans or MRIs and none required neurosurgical ...
... than white Americans, even when they have some ... is so, researchers at Columbia University,s Mailman School ... Medicine, surveyed African American adults with recent oral ... findings provide insights into why disparities persist even ...
... DALLAS June 16, 2011 UT Southwestern Medical ... anesthetic drug ketamine produces a fast-acting antidepressant response in ... robust effect at low doses as a fast-acting antidepressant ... "Ketamine produces a very sharp increase that ...
... esophagus may have a lower risk of esophageal cancer ... published online June 16 in the Journal of ... a premalignant condition, and patients who have it are ... signs of esophageal adenocarcinoma, the most common kind of ...
... -- The risk of cancer associated with the condition ... thought, according to a new long-term study. ... undergo routine endoscopies to screen for esophageal adenocarcinoma, a ... a long, thin tube with a camera at the ...
... Louis Children,s Hospital in the summer of 2010 near death ... lungs. Washington University physicians and surgeons at St. Louis ... his life. They collaborated to make several strategic and innovative ... artificial lung in a toddler. Their efforts are reported ...
Cached Medicine News:Health News:Hospitalizing children with normal CT scans after blunt head trauma is not necessary 2Health News:Hospitalizing children with normal CT scans after blunt head trauma is not necessary 3Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 2Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 3Health News:Barrett's esophagus carries lower risk of malignancy than previously reported 2Health News:Cancer Risk With Barrett's Esophagus May Be Lower Than Thought 2Health News:Washington University surgeons successfully use artificial lung in toddler 2Health News:Washington University surgeons successfully use artificial lung in toddler 3Health News:Washington University surgeons successfully use artificial lung in toddler 4
... important part of managing the disease state ... mean delivering the aerosolized medication to the ... medication waste. Aerosol delivery with the Salter ... including the new NebuTech® HDN®, helps to ...
Wire-wave tongs...
Tongs...
... vitro Nucleic Acid Hybridization Assay ... Chemiluminescence for the Qualitative Detection ... 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 and Analysis ... Groups in Cervical Specimens: HPV ...
Medicine Products: